se ha leído el artículo
array:25 [ "pii" => "S0001731022002861" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.05.027" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "3000" "copyright" => "AEDV" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2022;113:T529-T531" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S0001731021004580" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.08.034" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2840" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2022;113:532-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Estudio de eficacia y supervivencia de apremilast en 65 pacientes con psoriasis y artritis psoriásica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "532" "paginaFinal" => "535" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1787 "Ancho" => 2500 "Tamanyo" => 186143 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evolución de las escalas en los pacientes con psoriasis tratados con apremilast. PASI: Psoriasis Area and Severity Index; NAPSI: Nail Psoriasis Severity Index; PGA: Physician Global Assessment; DLQI: Dermatology Life Quality Index.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Garbayo Salmons, V. Expósito Serrano, J. Romaní de Gabriel, M. Ribera Pibernat" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Garbayo Salmons" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Expósito Serrano" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Romaní de Gabriel" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Ribera Pibernat" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021004580?idApp=UINPBA000044" "url" => "/00017310/0000011300000005/v1_202206110542/S0001731021004580/v1_202206110542/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0001731021004191" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.05.021" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2810" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2022;113:529-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científico-clínica</span>" "titulo" => "Micosis fungoides en estadio avanzado CD30+ tratadas con brentuximab" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "529" "paginaFinal" => "531" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Advanced-Stage CD30<span class="elsevierStyleSup">+</span> Mycosis Fungoides Treated With Brentuximab" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 927 "Ancho" => 1255 "Tamanyo" => 135673 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta clínica y radiológica de 2 de los pacientes en tratamiento con brentuximab. a) Lesiones cutáneas en la paciente número 1 antes de iniciar el tratamiento sistémico. b) Respuesta clínica en piel a las 6 semanas de inicio del tratamiento, con una disminución del eritema y la infiltración, así como de la extensión de las lesiones. c) Corte axial de TAC de tórax con contraste. Masas tumorales en ambos campos pulmonares correspondientes a una proliferación de linfocitos CD4+, CD30+. d) Desaparición completa de las masas tumorales tras la octava infusión de brentuximab.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Vico-Alonso, J.J. Andrés-Lencina, J.L. Rodríguez-Peralto, P.L. Ortiz Romero" "autores" => array:4 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "Vico-Alonso" ] 1 => array:2 [ "nombre" => "J.J." "apellidos" => "Andrés-Lencina" ] 2 => array:2 [ "nombre" => "J.L." "apellidos" => "Rodríguez-Peralto" ] 3 => array:2 [ "nombre" => "P.L." "apellidos" => "Ortiz Romero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021004191?idApp=UINPBA000044" "url" => "/00017310/0000011300000005/v1_202206110542/S0001731021004191/v1_202206110542/es/main.assets" ] "asociados" => array:1 [ 0 => array:19 [ "pii" => "S0001731021004191" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.05.021" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2810" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2022;113:529-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científico-clínica</span>" "titulo" => "Micosis fungoides en estadio avanzado CD30+ tratadas con brentuximab" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "529" "paginaFinal" => "531" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Advanced-Stage CD30<span class="elsevierStyleSup">+</span> Mycosis Fungoides Treated With Brentuximab" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 927 "Ancho" => 1255 "Tamanyo" => 135673 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta clínica y radiológica de 2 de los pacientes en tratamiento con brentuximab. a) Lesiones cutáneas en la paciente número 1 antes de iniciar el tratamiento sistémico. b) Respuesta clínica en piel a las 6 semanas de inicio del tratamiento, con una disminución del eritema y la infiltración, así como de la extensión de las lesiones. c) Corte axial de TAC de tórax con contraste. Masas tumorales en ambos campos pulmonares correspondientes a una proliferación de linfocitos CD4+, CD30+. d) Desaparición completa de las masas tumorales tras la octava infusión de brentuximab.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Vico-Alonso, J.J. Andrés-Lencina, J.L. Rodríguez-Peralto, P.L. Ortiz Romero" "autores" => array:4 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "Vico-Alonso" ] 1 => array:2 [ "nombre" => "J.J." "apellidos" => "Andrés-Lencina" ] 2 => array:2 [ "nombre" => "J.L." "apellidos" => "Rodríguez-Peralto" ] 3 => array:2 [ "nombre" => "P.L." "apellidos" => "Ortiz Romero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021004191?idApp=UINPBA000044" "url" => "/00017310/0000011300000005/v1_202206110542/S0001731021004191/v1_202206110542/es/main.assets" ] ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => " Advanced-Stage CD30<span class="elsevierStyleSup">+</span> Mycosis Fungoides Treated With Brentuximab" "tieneTextoCompleto" => true "saludo" => "To the Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T529" "paginaFinal" => "T531" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "C. Vico-Alonso, J.J. Andrés-Lencina, J.L. Rodríguez-Peralto, P.L. Ortiz Romero" "autores" => array:4 [ 0 => array:4 [ "nombre" => "C." "apellidos" => "Vico-Alonso" "email" => array:1 [ 0 => "c.vicoalonso@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J.J." "apellidos" => "Andrés-Lencina" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "J.L." "apellidos" => "Rodríguez-Peralto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "P.L." "apellidos" => "Ortiz Romero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Anatomía Patológica, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Micosis fungoides en estadio avanzado CD30+ tratadas con brentuximab" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 927 "Ancho" => 1255 "Tamanyo" => 136665 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical and radiological response of 2 patients treated with brentuximab. A, Skin lesions in Patient 1 before starting systemic treatment. B, Clinical cutaneous response 6 weeks after starting treatment, showing a decrease in erythema and infiltration, and in the extent of the lesions. C, Axial section of contrast computed tomography scan of the chest. Tumor masses in both lung fields correspond to a proliferation of CD4<span class="elsevierStyleSup">+</span>/CD30<span class="elsevierStyleSup">+</span> lymphocytes. D, Complete disappearance of the tumor masses after eighth infusion of brentuximab.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Mycosis fungoides (MF) accounts for 60% of cutaneous lymphomas. Although it generally has an indolent course, 25% of cases progress to advanced stages, with a median survival of 68 months in stage IIB and 33 months in stage IVB.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a> The therapeutic options for patients in these stages are limited. New molecules that have emerged in recent years include brentuximab vedotin (BV) for the treatment of CD30<span class="elsevierStyleSup">+</span> MF.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We describe a series of 5 cases (2 women and 3 men) of advanced CD30<span class="elsevierStyleSup">+</span> MF treated with BV. The median age at diagnosis was 67 (range, 52–83) years. The cases corresponded to erythrodermic MF (1 patient), interstitial MF (1 patient), and MF with large cell transformation (3 patients).<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">3</span></a> In all cases immunohistochemistry was positive for CD30, with expression exceeding 20% in some skin samples taken before starting treatment. The mean time since disease onset was 4.8 years. The mean number of previous treatments received by each patient was 6.6 (range, 4–9) and the median BV treatment duration was 3 cycles (range, 1–16) (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Patient 1, a 59-year-old woman with stage T4N0M0B0 MF, exhibited a clinical cutaneous response 6 weeks after starting treatment, with a response duration of 12 months (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A and B). Patient 2, an 83-year-old man with stage T3N0M1B2 MF, showed a partial cutaneous response at 12 weeks. This patient presented CD4<span class="elsevierStyleSup">+</span>/CD30<span class="elsevierStyleSup">+</span> lymphocytic infiltration in both lungs, and showed a response in viscera 15 weeks after starting treatment (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>C and D). The duration of the response in viscera was 9 months. Patient 3, a 63-year-old man with stage T3N3M1B0 MF with tumor lesions, presented a rapid cutaneous response 2 weeks after starting treatment, with subsequent progression of both lymph node and visceral disease. Patient 4, a 76-year-old woman with erythrodermic stage T4N0M0B2 MF, experienced disease progression. Patient 5, a 52-year-old man with interstitial MF with tumor lesions (stage T3NxM0B0), showed a partial cutaneous response after 2 weeks, with subsequent progression of cutaneous and lymph node disease.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">In summary, a partial cutaneous response was observed in 4 patients, of whom 2 experienced disease progression, while 1 patient showed a complete response in viscera. The median time to clinical response was 6 (range, 2–12) weeks (skin) and 15 weeks (viscera). In the 2 patients who showed a response to treatment (partial cutaneous response, complete response in viscera), without progression, the overall response duration was 9 and 12 months, respectively.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The most frequent adverse events were peripheral sensory neuropathy (maximum, grade 3), which appeared after a mean number of 2 infusions, followed by asthenia and arthralgia. None of these events necessitated treatment discontinuation. In 1 patient sensory neuropathy had resolved upon completion of BV treatment, while in the other it persisted up to 16 weeks after completion.</p><p id="par0030" class="elsevierStylePara elsevierViewall">BV is a monoclonal antibody for CD30, a transmembrane glycoprotein expressed on activated B and T lymphocytes. This antibody is bound to monomethyl auristatin E (MMAE), an agent that disrupts the microtubule network leading to cell cycle arrest and subsequent apostosis.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">4</span></a> The multicenter, randomized, phase 3 ALCANZA clinical trial concluded that BV treatment was superior to both bexarotene and methotrexate, regardless of age, sex, type of cutaneous lymphoma (CD30<span class="elsevierStyleSup">+</span> MF or cutaneous anaplastic large cell lymphoma), or involvement (cutaneous or cutaneous and visceral).<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">5</span></a> However, up to a third of the patients had early-stage disease and a median of only 2 previous lines of treatment, thereby excluding, in our opinion, the majority of patients who receive this type of treatment in routine clinical practice. Papadavid et al. have shared their experience with BV treatment in 3 patients with folliculotropic MF and large cell transformation and 1 patient with Sézary syndrome (SS).<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">6</span></a> The 3 MF patients showed complete or partial responses, while the SS patient presented stable disease.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">The most surprising finding in our case series was the rapid cutaneous response after the first infusion. This was particularly evident in the case of tumor lesions, which had been rapidly progressing to skin necrosis. Patient 5, who had a diagnosis of interstitial MF and tumor-like skin lesions, experienced this effect after a single dose of BV. Another interesting finding was the complete response in viscera, according to the relevant criterion, which was observed in a patient with specific pulmonary involvement and was maintained for 9 months.</p><p id="par0040" class="elsevierStylePara elsevierViewall">In our experience BV offers a rapid tumor response, although maintenance of this response is highly variable. Knowledge of the type of patient and the disease stage is necessary to ensure optimal use. Furthermore, new studies are required to best position the drug in clinical practice, including its combination with other agents and maintenance therapy in cases in which a response is achieved.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0045" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of Interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 927 "Ancho" => 1255 "Tamanyo" => 136665 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical and radiological response of 2 patients treated with brentuximab. A, Skin lesions in Patient 1 before starting systemic treatment. B, Clinical cutaneous response 6 weeks after starting treatment, showing a decrease in erythema and infiltration, and in the extent of the lesions. C, Axial section of contrast computed tomography scan of the chest. Tumor masses in both lung fields correspond to a proliferation of CD4<span class="elsevierStyleSup">+</span>/CD30<span class="elsevierStyleSup">+</span> lymphocytes. D, Complete disappearance of the tumor masses after eighth infusion of brentuximab.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>: BV, brentuximab vedotin; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; DP, disease progression; INF, interferon; LCT, large cell transformation; MF, mycosis fungoides; Mtx-IL, intralesional methotrexate; NA, not applicable; PEG-INF, pegylated interferon; PUVA, psoralen-ultraviolet A; PR, partial response; RT, radiotherapy; TSEB, total skin electron beam therapy; TNMB, tumor-node-metastasis-blood.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 2 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 4 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 5 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SexClinicopathological variant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FemaleMF with LCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MaleMF with LCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MaleMF with LCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FemaleErythrodermic MF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MaleInterstitial MF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prior treatments \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Phototherapy, INF, PEG-INF, bexarotene, methotrexate, mogamulizumab, liposomal doxorubicin, TSEB, photopheresis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mtx-IL, alitretinoin, acitretin, liposomal doxorubicin, CHOP, bexarotene, vorinostat, mogamulizumab, INF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PUVA, gemcitabine, TSEB, alemtuzumab, liposomal doxorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PUVA, mogamulizumab, bexarotene, liposomal doxorubicin, vorinostat \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">acitretin, bexarotene, RT, liposomal doxorubicin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical stage/TNMB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T4N0M0B0 IIIA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T3N0M1B2 IVB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T3N3M1B0 IVB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T4N0M0B2 IVA1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T3NxM0B0 IIB \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous response<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">7</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lymph node response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Response in viscera \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Response in blood \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Overall response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DP \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of BV cycles \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adverse effects \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Paresthesia Arthralgia Myalgia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Paresthesia Asthenia Arthralgia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Clinical Characteristics of Patients and Clinical Response to Treatment.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib0040" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "J.J. Scarisbrick" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2015.61.7142" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "3766" "paginaFinal" => "3773" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26438120" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0045" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Results of a phase ii trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "M. Duvic" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2014.60.3787" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "3759" "paginaFinal" => "3765" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26261247" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0050" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinicopathologic variants of mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H. Muñoz-González" 1 => "A.-M. Molina-Ruiz" 2 => "L. Requena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2016.08.009" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2017" "volumen" => "108" "paginaInicial" => "192" "paginaFinal" => "208" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27871620" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0055" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brentuximab vedotin in CD30+cutaneous lymphoma: how do we treat, how shall we treat? A review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Stranzenbach" 1 => "E. Dippel" 2 => "M. Schlaak" 3 => "R. Stadler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.15801" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2017" "volumen" => "177" "paginaInicial" => "1503" "paginaFinal" => "1509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28703284" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0060" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.M. Prince" 1 => "Y.H. Kim" 2 => "S.M. Horwitz" 3 => "R. Dummer" 4 => "J. Scarisbrick" 5 => "P. Quaglino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(17)31266-7" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "390" "paginaInicial" => "555" "paginaFinal" => "566" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28600132" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0065" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of brentuximab vedotin in advanced cutaneous T-cell lymphomas patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Papadavid" 1 => "E. Kapniari" 2 => "L. Marinos" 3 => "V. Nikolaou" 4 => "A. Oikonomidi" 5 => "J. Georgakopoulos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Eur Acad Dermatol Venerol" "fecha" => "2019" "volumen" => "33" "paginaInicial" => "e223" "paginaFinal" => "e232295" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0070" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.A. Olsen" 1 => "S. Whittaker" 2 => "Y.H. Kim" 3 => "M. Duvic" 4 => "H.M. Prince" 5 => "S.R. Lessin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.32.0630" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "2598" "paginaFinal" => "2607" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21576639" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011300000005/v1_202206110542/S0001731022002861/v1_202206110542/en/main.assets" "Apartado" => array:4 [ "identificador" => "92870" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Cartas científico-clínicas / Case and Research Letter" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011300000005/v1_202206110542/S0001731022002861/v1_202206110542/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731022002861?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 5 | 2 | 7 |
2024 Octubre | 121 | 48 | 169 |
2024 Septiembre | 123 | 32 | 155 |
2024 Agosto | 133 | 61 | 194 |
2024 Julio | 95 | 41 | 136 |
2024 Junio | 91 | 53 | 144 |
2024 Mayo | 85 | 49 | 134 |
2024 Abril | 99 | 29 | 128 |
2024 Marzo | 105 | 52 | 157 |
2024 Febrero | 90 | 37 | 127 |
2024 Enero | 94 | 31 | 125 |
2023 Diciembre | 68 | 24 | 92 |
2023 Noviembre | 92 | 36 | 128 |
2023 Octubre | 85 | 43 | 128 |
2023 Septiembre | 117 | 30 | 147 |
2023 Agosto | 94 | 23 | 117 |
2023 Julio | 77 | 34 | 111 |
2023 Junio | 61 | 25 | 86 |
2023 Mayo | 94 | 35 | 129 |
2023 Abril | 57 | 20 | 77 |
2023 Marzo | 66 | 26 | 92 |
2023 Febrero | 56 | 30 | 86 |
2023 Enero | 55 | 56 | 111 |
2022 Diciembre | 64 | 46 | 110 |
2022 Noviembre | 96 | 42 | 138 |
2022 Octubre | 71 | 53 | 124 |
2022 Septiembre | 67 | 44 | 111 |
2022 Agosto | 110 | 60 | 170 |
2022 Julio | 128 | 51 | 179 |
2022 Junio | 119 | 49 | 168 |
2022 Mayo | 74 | 51 | 125 |
2022 Abril | 34 | 35 | 69 |